Cerus lowers Intercept sales guidance after Fresenius Kabi supply snafu

Cerus (NSDQ:CERS) said today that it expects a U.S. supply shortage of Fresenius Kabi’s (NYSE:FMS) platelet additive solution will impact blood centers that use PAS to produce Intercept platelets.

The pending shortage is due to “an unanticipated delay” in FDA approval of a plastic component used to manufacture the PAS container. The original component was discontinued by Fresenius Kabi’s supplier, the company reported.

Get the full story at our sister site, Drug Delivery Business News.

The post Cerus lowers Intercept sales guidance after Fresenius Kabi supply snafu appeared first on MassDevice.

from MassDevice http://ift.tt/2q7gjRv